유전자 재조합 마우스 상피성장인자 시약 시장 보고서 : 동향, 예측 및 경쟁 분석(-2031년)
Recombinant Mouse Epidermal Growth Factor Reagent Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드:1801419
리서치사:Lucintel
발행일:2025년 08월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 유전자 재조합 마우스 상피성장인자 시약 시장 전망은 유망하며, 생물학 연구소와 대학 시장에서의 기회가 기대됩니다. 유전자 재조합 마우스 상피성장인자 시약 세계 시장은 2025-2031년 연평균 10.5%의 성장률을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 상처 치유에 대한 수요 증가, 화장품 제형에 대한 사용 증가, 조직 재생에 대한 연구 증가입니다.
Lucintel의 예측에 따르면, 유형별로는 순도 95% 이상이 예측 기간 동안 높은 성장세를 보일 것으로 예측됩니다.
용도별로는 생물학 연구실이 더 높은 성장을 이룰 것으로 예측됩니다.
지역별로는 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예측됩니다.
유전자 재조합 마우스 상피세포성장인자 시약 시장의 새로운 트렌드
유전자 변형 마우스 상피성장 인자 시약 시장은 생물 의학 연구 요구의 진화, 실험 재현성 향상 추진, 단백질 생산의 발전에 의해 형성된 몇 가지 주요 신흥 동향을 목격하고 있습니다. 이러한 추세는 다양한 과학적 시도를 지원하기 위해 더 높은 품질, 더 전문적이고 윤리적으로 조달된 시약으로의 전환을 강조하고 있습니다.
비동물성 시약: 비동물성 시스템에서 생산된 재조합 마우스 EGF 시약에 대한 수요가 강하고 증가하고 있습니다. 이러한 추세는 불확정성 요인의 위험을 최소화하고, 고감도 연구 및 잠재적 임상 적용을 위해 일관되게 정의된 세포 배양 조건을 보장해야 할 필요성에 의해 추진되고 있습니다.
순도 및 생리활성 향상: 제조업체들은 순도가 높고 생물학적 활성이 입증된 재조합 마우스 EGF 생산에 주력하고 있습니다. 이를 통해 세포 배양 실험, 신호전달 경로 연구, 약물 스크리닝 분석에서 과학적 무결성에 매우 중요한 신뢰성과 재현성이 높은 결과를 보장합니다.
유기체 및 3차원 세포 배양에 적용: 유기체 및 3차원 세포 배양 분야는 빠르게 성장하고 있으며, 재조합 마우스 EGF에 대한 수요가 증가하고 있습니다. EGF는 다양한 유형의 유기체를 유지 및 확대하기 위해 화학적으로 정의된 많은 배지에서 중요한 성분이며, 질병 연구를 위한 보다 생리학적으로 적합한 체외 모델을 촉진합니다.
비용 효율적이고 확장 가능한 생산: 연구가 전 세계적으로 확대됨에 따라 재조합 마우스 EGF 시약의 비용 효율적이고 확장 가능한 생산 방법에 대한 요구가 증가하고 있습니다. 여기에는 더 많은 연구자들이 고품질의 시약을 사용할 수 있도록 발현 시스템 및 정제 과정을 최적화하는 것도 포함됩니다.
특수 변이체 개발: 연구 개발자들은 재조합 마우스 EGF의 특수한 변이체 및 개량형을 탐색 및 개발하고 있습니다. 이러한 변이체는 안정성 향상, 수용체 결합 특이성 변경, 활성 연장 등을 제공하여 마우스 모델에 대한 특정 연구 요구 및 치료제 개발에 대응하고 있습니다.
이러한 추세는 전체적으로 재조합 마우스 EGF 시약 시장을 보다 정교하고 윤리의식이 높은 고성능 산업으로 재구성하고 있습니다. 명확하게 정의된 고품질, 용도별 시약에 초점을 맞추는 것은 생의학 연구를 발전시키고, 보다 복잡한 체외 모델을 가능하게 하며, 미래 치료 전략 개발을 지원하는 데 매우 중요합니다.
유전자 재조합 마우스 상피세포성장인자 시약 시장의 최근 트렌드
유전자 변형 마우스 상피성장 인자 시약 시장은 많은 생물학적 연구 응용 분야에서 기초적인 역할과 실험 모델의 고도화로 인해 지속적으로 개척되고 있습니다. 최근 주요 동향은 생산 방식, 품질 관리, 다양한 과학 분야에서의 유용성 확대에 대한 획기적인 발전에 초점을 맞추었습니다.
개선된 발현 시스템: 제조업체들은 재조합 마우스 EGF 생산에 고급 미생물 및 포유류 발현 시스템을 사용하여 수율 향상, 접힘 개선, 생물학적 활성 강화로 이어져 생산 효율성과 비용 효율성을 높이고 있습니다.
향상된 정제 기술: 보다 정교한 크로마토그래피 및 여과 방법을 사용하여 오염 물질을 최소화하고 고감도 세포 배양 및 생화학 분석에서 일관되고 신뢰할 수 있는 성능을 보장하는 고순도 재조합 마우스 EGF 시약을 생산하고 있습니다.
동물 유래 성분을 전혀 포함하지 않는 재조합 마우스 EGF 시약의 광범위한 가용성은 중요한 발전입니다. 이는 불순물에 대한 우려를 해소하고, 보다 명확하고 일관된 세포 배양 시약을 제공합니다.
유기체 및 3D 배양 시스템에서의 사용 확대: 재조합 마우스 EGF는 빠르게 성장하고 있는 유기체 및 3D 세포 배양 분야에서 없어서는 안 될 성분으로 자리 잡고 있습니다. 이러한 복잡한 모델에서 세포 증식과 생존을 촉진하는 데 중요한 역할을 하기 때문에 수요가 증가하여 특수한 제제가 개발되고 있습니다.
시판되는 세포 배양 배지에 통합: 현재 많은 시판되는 화학적으로 정의된 세포 배양 배지는 재조합 마우스 EGF를 표준 성분으로 함유하고 있습니다. 이 통합은 연구자의 워크플로우를 간소화하고, 다양한 유형의 세포의 최적의 증식과 분화를 보장하며, 실험의 재현성을 높입니다.
이러한 개발은 연구자들에게 더 높은 품질, 더 신뢰할 수 있고 더 안전한 도구를 제공함으로써 재조합 마우스 EGF 시약 시장에 종합적인 영향을 미치고 있습니다. 생산성, 순도 향상, 최신 세포 배양 기술과의 통합에 초점을 맞추는 것은 과학적 발견을 가속화하고 빠르게 진화하는 생물 의학 연구 상황을 지원하는 데 매우 중요합니다.
목차
제1장 주요 요약
제2장 시장 개요
배경과 분류
공급망
제3장 시장 동향과 예측 분석
거시경제 동향과 예측
업계 촉진요인과 과제
PESTLE 분석
특허 분석
규제 환경
제4장 세계의 유전자 재조합 마우스 상피성장인자 시약 시장 : 유형별
개요
매력 분석 : 유형별
순도95% 이상 : 동향과 예측(2019-2031년)
순도95% 이하 : 동향과 예측(2019-2031년)
제5장 용도별 유전자 재조합 마우스 상피성장인자 시약 시장
개요
용도별 매력 분석
생물학 연구소 : 동향과 예측(2019-2031년)
대학 : 동향과 예측(2019-2031년)
기타 : 동향과 예측(2019-2031년)
제6장 지역 분석
개요
세계의 유전자 재조합 마우스 상피성장인자 시약 시장 : 지역별
제7장 북미의 유전자 재조합 마우스 상피성장인자 시약 시장
개요
북미의 유전자 재조합 마우스 상피성장인자 시약 시장 : 유형별
북미의 유전자 재조합 마우스 상피성장인자 시약 시장 : 용도별
미국의 유전자 재조합 마우스 상피성장인자 시약 시장
멕시코의 유전자 재조합 마우스 상피성장인자 시약 시장
캐나다의 유전자 재조합 마우스 상피성장인자 시약 시장
제8장 유럽의 유전자 재조합 마우스 상피성장인자 시약 시장
개요
유럽의 유전자 재조합 마우스 상피성장인자 시약 시장 : 유형별
유럽의 유전자 재조합 마우스 상피성장인자 시약 시장 : 용도별
독일의 유전자 재조합 마우스 상피성장인자 시약 시장
프랑스의 유전자 재조합 마우스 상피성장인자 시약 시장
스페인의 유전자 재조합 마우스 상피성장인자 시약 시장
이탈리아의 유전자 재조합 마우스 상피성장인자 시약 시장
영국 유전자 재조합 마우스 상피성장인자 시약 시장
제9장 아시아태평양의 유전자 재조합 마우스 상피성장인자 시약 시장
개요
아시아태평양의 유전자 재조합 마우스 상피성장인자 시약 시장 : 유형별
아시아태평양의 유전자 재조합 마우스 상피성장인자 시약 시장 : 용도별
일본의 유전자 재조합 마우스 상피성장인자 시약 시장
인도의 유전자 재조합 마우스 상피성장인자 시약 시장
중국의 유전자 재조합 마우스 상피성장인자 시약 시장
한국의 유전자 재조합 마우스 상피성장인자 시약 시장
인도네시아의 유전자 재조합 마우스 상피성장인자 시약 시장
제10장 기타 지역(ROW)의 유전자 재조합 마우스 상피성장인자 시약 시장
개요
기타 지역(ROW)의 유전자 재조합 마우스 상피성장인자 시약 시장 : 유형별
기타 지역(ROW)의 유전자 재조합 마우스 상피성장인자 시약 시장 : 용도별
중동의 유전자 재조합 마우스 상피성장인자 시약 시장
남미의 유전자 재조합 마우스 상피성장인자 시약 시장
아프리카의 유전자 재조합 마우스 상피성장인자 시약 시장
제11장 경쟁 분석
제품 포트폴리오 분석
운영 통합
Porter의 Five Forces 분석
경쟁 기업간 경쟁 관계
바이어의 교섭력
공급업체의 교섭력
대체품의 위협
신규 진출업체의 위협
시장 점유율 분석
제12장 기회와 전략 분석
밸류체인 분석
성장 기회 분석
성장 기회 : 유형별
성장 기회 : 용도별
세계 유전자 재조합 마우스 상피성장인자 시약 시장의 새로운 동향
전략 분석
신제품 개발
인증 및 라이선싱
인수합병(M&A), 계약, 제휴 및 합작투자(JV)
제13장 밸류체인 주요 기업 개요
Competitive Analysis
Novartis
Amgen
Betta Pharmaceuticals
Thermo Fisher Scientific
Eli Lilly and Company
Bio-Techne
Merck
Yeasen
Sino Biological
Miltenyi Biotec
제14장 부록
그림 리스트
표 리스트
분석 방법
면책사항
저작권
약어와 기술 단위
Lucintel에 대해
문의
LSH
영문 목차
영문목차
The future of the global recombinant mouse epidermal growth factor reagent market looks promising with opportunities in the biological laboratory and university markets. The global recombinant mouse epidermal growth factor reagent market is expected to grow with a CAGR of 10.5% from 2025 to 2031. The major drivers for this market are the increasing demand for wound healing, the rising use in cosmetic formulations, and the growing research in tissue regeneration.
Lucintel forecasts that, within the type category, purity >95% is expected to witness higher growth over the forecast period.
Within the application category, biological laboratory is expected to witness higher growth.
In terms of region, North America is expected to witness the highest growth over the forecast period.
Emerging Trends in the Recombinant Mouse Epidermal Growth Factor Reagent Market
The recombinant mouse epidermal growth factor reagent market is witnessing several key emerging trends, shaped by the evolving needs of biomedical research, the push for greater experimental reproducibility, and advancements in protein production. These trends highlight a shift towards higher quality, more specialized, and ethically sourced reagents to support diverse scientific endeavors.
Animal-Origin-Free Reagents: There is a strong and increasing demand for recombinant mouse EGF reagents produced in animal-origin-free systems. This trend is driven by the need to minimize the risk of adventitious agents and to ensure consistent, defined cell culture conditions for sensitive research and potential clinical applications.
Enhanced Purity and Bioactivity: Manufacturers are focusing on producing recombinant mouse EGF with significantly higher purity levels and proven biological activity. This ensures reliable and reproducible results in cell culture experiments, signaling pathway studies, and drug screening assays, which are critical for scientific integrity.
Application in Organoid and 3D Cell Culture: The burgeoning fields of organoid and 3D cell culture are driving increased demand for recombinant mouse EGF. It is a vital component in many chemically defined media for maintaining and expanding various organoid types, facilitating more physiologically relevant in vitro models for disease research.
Cost-Effective and Scalable Production: As research expands globally, there is a growing need for cost-effective and scalable production methods for recombinant mouse EGF reagents. This includes optimizing expression systems and purification processes to make high-quality reagents more accessible to a wider range of researchers.
Development of Specialized Variants: Researchers are exploring and developing specialized variants or modified forms of recombinant mouse EGF. These variants may offer enhanced stability, altered receptor binding specificities, or prolonged activity, catering to specific research needs or therapeutic development for murine models.
These trends are collectively reshaping the recombinant mouse EGF reagent market towards a more sophisticated, ethically conscious, and high-performance industry. The emphasis on defined, high-quality, and application-specific reagents is crucial for advancing biomedical research, enabling more complex in vitro models, and supporting the development of future therapeutic strategies.
Recent Developments in the Recombinant Mouse Epidermal Growth Factor Reagent Market
The recombinant mouse epidermal growth factor reagent market is undergoing continuous development, primarily driven by its foundational role in numerous biological research applications and the increasing sophistication of experimental models. Recent key developments highlight significant advancements in production methodologies, quality control, and the expansion of its utility across various scientific disciplines.
Improved Expression Systems: Manufacturers are increasingly utilizing advanced microbial and mammalian expression systems for recombinant mouse EGF production, leading to higher yields, improved folding, and enhanced biological activity, thereby increasing the efficiency and cost-effectiveness of production.
Enhanced Purification Techniques: The adoption of more sophisticated chromatography and filtration methods has resulted in recombinant mouse EGF reagents with exceptionally high purity, minimizing contaminants and ensuring consistent, reliable performance in sensitive cell culture and biochemical assays.
Introduction of Animal-Free Products: A significant development is the widespread availability of recombinant mouse EGF reagents produced without any animal-derived components. This addresses concerns about adventitious agents and provides a more defined and consistent reagent for cell culture.
Expanding Use in Organoid and 3D Culture Systems: Recombinant mouse EGF is becoming an indispensable component in the rapidly growing field of organoid and 3D cell culture. Its critical role in promoting cell proliferation and survival in these complex models has driven increased demand and specialized formulations.
Integration into Commercial Cell Culture Media: Many commercially available, chemically defined cell culture media now include recombinant mouse EGF as a standard component. This integration streamlines workflows for researchers, ensuring optimal growth and differentiation of various cell types, enhancing experimental reproducibility.
These developments are collectively impacting the recombinant mouse EGF reagent market by providing researchers with higher quality, more reliable, and safer tools. The focus on improved production, purity, and integration into modern cell culture techniques is crucial for accelerating scientific discovery and supporting the rapidly evolving landscape of biomedical research.
Strategic Growth Opportunities in the Recombinant Mouse Epidermal Growth Factor Reagent Market
The recombinant mouse epidermal growth factor reagent market offers several strategic growth opportunities by targeting specific applications that leverage its potent cell proliferation and differentiation capabilities. By focusing on areas with high research intensity and evolving experimental needs, manufacturers can expand their market presence and drive innovation, contributing to advancements in various life science disciplines.
Stem Cell Research and Culture: The rapidly expanding field of stem cell research, including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), provides a significant opportunity for recombinant mouse EGF as a critical component in chemically defined media for maintaining pluripotency and promoting differentiation.
Organoid and 3D Cell Culture Models: The increasing adoption of organoid and 3D cell culture systems for disease modeling, drug screening, and regenerative medicine offers a robust growth area. Recombinant mouse EGF is essential for supporting the growth and integrity of various tissue-specific organoids.
Wound Healing and Tissue Repair Studies: Research into wound healing mechanisms and tissue regeneration heavily utilizes recombinant mouse EGF due to its known role in stimulating epidermal cell proliferation and migration. This application provides a steady demand for high-quality reagents in dermatology and regenerative medicine research.
Cancer Research and Drug Discovery: The role of EGF and its receptor (EGFR) in cancer progression and metastasis creates a strong demand for recombinant mouse EGF as a reagent in oncology research, including in vitro assays for anti-cancer drug screening and understanding signaling pathways.
Development of In Vitro Fertilization (IVF) Media: Recombinant mouse EGF is increasingly used in specialized media for in vitro fertilization (IVF) research and procedures, particularly in murine models. Its role in supporting oocyte maturation and embryonic development offers a niche but important growth opportunity.
These strategic growth opportunities are reshaping the recombinant mouse EGF reagent market by directing investment and innovation towards high-impact research areas. By focusing on critical applications, manufacturers can develop tailored solutions, support cutting-edge scientific inquiries, and solidify the market's role as a fundamental supplier for advancing biological and medical understanding.
Recombinant Mouse Epidermal Growth Factor Reagent Market Driver and Challenges
The recombinant mouse epidermal growth factor reagent market is influenced by a dynamic interplay of factors. Major drivers include the expanding scope of cell culture research, the growth of organoid and 3D culture technologies, and increasing investment in life science research. However, significant challenges such as high production costs, maintaining lot-to-lot consistency, and competition from alternative growth factors pose considerable hurdles for market stakeholders.
The factors responsible for driving the recombinant mouse epidermal growth factor reagent market include:
1. Expanding Cell Culture Research: The continuous growth in basic and applied cell culture research across various disciplines, including developmental biology, neurobiology, and immunology, directly drives the demand for recombinant mouse EGF as a crucial growth factor.
2. Growth of Organoid and 3D Culture Technologies: The rapid adoption of more complex and physiologically relevant organoid and 3D cell culture models in drug discovery and disease modeling necessitates the use of high-quality recombinant mouse EGF for maintaining cellular health and tissue architecture.
3. Increasing Investment in Life Science Research: Global increases in funding for biotechnology, pharmaceutical research, and academic life sciences fuel the demand for high-quality research reagents, including recombinant mouse EGF, to support a wide array of experimental designs.
4. Demand for Defined and Animal-Free Media: The industry's shift towards chemically defined and animal-origin-free cell culture media to reduce variability and ensure reproducibility is a significant driver for high-purity recombinant mouse EGF reagents.
5. Role in Pre-clinical Drug Discovery: Recombinant mouse EGF is an essential component in many in vitro and in vivo pre-clinical drug discovery assays, particularly those involving cell proliferation, differentiation, and receptor signaling, ensuring its continued relevance in pharmaceutical R&D.
Challenges in the recombinant mouse epidermal growth factor reagent market are:
1. High Production and Purification Costs: The complexity of expressing, purifying, and validating recombinant mouse EGF to achieve high purity and biological activity results in relatively high manufacturing costs, which can impact the overall price of the reagent for researchers.
2. Maintaining Lot-to-Lot Consistency: Ensuring consistent biological activity and purity across different production batches of recombinant mouse EGF can be challenging. Batch variability can affect experimental reproducibility, posing a significant concern for researchers.
3. Competition from Alternative Growth Factors: While essential for specific applications, recombinant mouse EGF faces competition from other growth factors or synthetic alternatives that might offer similar proliferative effects or be preferred for certain cell types, potentially limiting its market share in some segments.
The market is significantly propelled by expanding cell culture research, the rise of 3D culture, and increased life science funding, underscoring its indispensable role. However, high production costs, the challenge of maintaining consistency, and competition from alternatives necessitate continuous innovation in manufacturing and quality control. Addressing these challenges is crucial for sustained growth and broader adoption of recombinant mouse EGF reagents in research.
List of Recombinant Mouse Epidermal Growth Factor Reagent Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, recombinant mouse epidermal growth factor reagent companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the recombinant mouse epidermal growth factor reagent companies profiled in this report include:
Novartis
Amgen
Betta Pharmaceuticals
Thermo Fisher Scientific
Eli Lilly and Company
Bio-Techne
Merck
Yeasen
Sino Biological
Miltenyi Biotec
Recombinant Mouse Epidermal Growth Factor Reagent Market by Segment
The study includes a forecast for the global recombinant mouse epidermal growth factor reagent market by type, application, and region.
Recombinant Mouse Epidermal Growth Factor Reagent Market by Type [Value from 2019 to 2031]:
Purity >95%
Purity <=95%
Recombinant Mouse Epidermal Growth Factor Reagent Market by Application [Value from 2019 to 2031]:
Biological Laboratories
University
Others
Recombinant Mouse Epidermal Growth Factor Reagent Market by Region [Value from 2019 to 2031]:
North America
Europe
Asia Pacific
The Rest of the World
Country Wise Outlook for the Recombinant Mouse Epidermal Growth Factor Reagent Market
The recombinant mouse epidermal growth factor reagent market is experiencing notable developments, driven by its indispensable role in cell culture, regenerative medicine research, and drug discovery. Recent advancements across the United States, China, Germany, India, and Japan reflect innovations in production technologies, enhanced purity standards, and the expanding application of mouse EGF in various biological studies.
United States: The US market for recombinant mouse EGF reagents is robust, propelled by extensive biotechnology research and development. Recent developments include increased demand for high-purity, animal-origin-free reagents for sensitive cell culture applications, and ongoing investment in advanced expression systems to ensure consistent quality and scalability for research institutions.
China: China's recombinant mouse EGF reagent market is growing significantly, supported by expanding life science research and a focus on domestic production. Recent developments include increased availability of locally produced recombinant mouse EGF, a focus on cost-effective manufacturing, and its widespread use in basic research, particularly in studies related to cell proliferation and differentiation.
Germany: The German market emphasizes precision and reliability in recombinant mouse EGF reagents, largely driven by strong academic and industrial research sectors. Recent developments include the adoption of advanced purification techniques for superior quality reagents, and a focus on providing highly active and consistent batches essential for reproducible experimental outcomes in cell biology.
India: India's recombinant mouse EGF reagent market is expanding, fueled by increasing investment in bioscience research and academic pursuits. Recent developments include the growing availability of various recombinant mouse EGF products from both international and domestic suppliers, and its increasing utility in cell culture media for academic and early-stage drug discovery research.
Japan: Japan's market for recombinant mouse EGF reagents prioritizes high-quality, specialized products for cutting-edge research. Recent developments include the strong demand for animal-free recombinant mouse EGF for organoid and stem cell culture, and continuous efforts to develop highly bioactive and stable forms essential for sophisticated in vitro studies and tissue engineering.
Features of the Global Recombinant Mouse Epidermal Growth Factor Reagent Market
Market Size Estimates: Recombinant mouse epidermal growth factor reagent market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Recombinant mouse epidermal growth factor reagent market size by type, application, and region in terms of value ($B).
Regional Analysis: Recombinant mouse epidermal growth factor reagent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the recombinant mouse epidermal growth factor market.
Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the recombinant mouse epidermal growth factor market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the recombinant mouse epidermal growth factor reagent market by type (purity >95% and purity <=95%), application (biological laboratories, university, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Market Overview
2.1 Background and Classifications
2.2 Supply Chain
3. Market Trends & Forecast Analysis
3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment
4. Global Recombinant Mouse Epidermal Growth Factor Reagent Market by Type
4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 Purity>95%: Trends and Forecast (2019-2031)
4.4 Purity<=95%: Trends and Forecast (2019-2031)
5. Global Recombinant Mouse Epidermal Growth Factor Reagent Market by Application
5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Biological Laboratories: Trends and Forecast (2019-2031)
5.4 University: Trends and Forecast (2019-2031)
5.5 Others: Trends and Forecast (2019-2031)
6. Regional Analysis
6.1 Overview
6.2 Global Recombinant Mouse Epidermal Growth Factor Reagent Market by Region
7. North American Recombinant Mouse Epidermal Growth Factor Reagent Market
7.1 Overview
7.2 North American Recombinant Mouse Epidermal Growth Factor Reagent Market by Type
7.3 North American Recombinant Mouse Epidermal Growth Factor Reagent Market by Application
7.4 United States Recombinant Mouse Epidermal Growth Factor Reagent Market
